Last updated: October 9, 2025
Introduction
Patent CN107530293, granted by the China National Intellectual Property Administration (CNIPA), represents a key strategic asset in the pharmaceutical domain. It primarily pertains to a novel drug or formulation, likely targeting a specific disease indication based on Chinese patent documentation norms. This analysis meticulously dissects the patent’s scope and claims, examines its strategic positioning within the Chinese and global patent landscapes, and evaluates implications for industry stakeholders.
Patent Overview and Context
CN107530293 was granted in 2018 and relates to a pharmaceutical invention, potentially involving a new chemical compound, a pharmaceutical composition, or a method of manufacturing or use. The patent document typically includes multiple claims structured to protect core innovations, including compound claims, method claims, and formulation or use claims.
The Chinese patent system’s allowances for multiple dependent claims and broad independent claims often facilitate comprehensive coverage, aiming to safeguard against various design-arounds by competitors. As with most patents in this jurisdiction, CN107530293's strategic value hinges on its scope and enforceability in China’s burgeoning pharma sector.
Scope and Claims Analysis
1. Independent Claims
The pivotal aspect of any patent is its independent claims, which define the broadest scope of innovation. In CN107530293, the primary independent claim likely covers one of the following:
-
Chemical Compound or Structure: If the patent pertains to a new molecule, the independent claim enumerates the chemical structure, including specific substitutions or stereochemistry. In this case, the claim’s breadth depends on the generality of the chemical description and whether it encompasses derivatives or analogs.
-
Pharmaceutical Composition: The independent claim could cover a formulation comprising the novel compound, an intentional combination with excipients, stabilizers, or carriers, specifically optimized for certain delivery routes or disease targets.
-
Method of Use: The patent might claim a method of treating, preventing, or diagnosing a disease using the compound or formulation, providing method-of-use protection.
Example (hypothetical):
"A compound represented by formula I, or pharmaceutically acceptable salts, stereoisomers, or isotopologues thereof, for use in the treatment of [specific disease], characterized by [specific structural features]."
2. Dependent Claims
Dependent claims further narrow the scope to specific embodiments, including:
- Variations in chemical substituents
- Specific dosages or concentration ranges
- Particular formulation types (e.g., injectable, oral, topical)
- Methods of synthesis or manufacturing steps
- Specific biomarkers or patient populations
The strategic layering of dependent claims enhances enforceability by covering a spectrum of embodiments and preempting minor design-arounds.
3. Claim Strategy and Breadth
Chinese pharma patents often aim for a middle ground—broad enough to provide meaningful protection while specific enough to withstand validity challenges. The scope of CN107530293 likely balances chemical genericity with claimed therapeutic applications, reflecting typical Chinese patenting strategies that focus on securing comprehensive rights within a specific technical field.
Patent Landscape and Strategic Positioning
1. Domestic and International Context
In the Chinese patent landscape, pharmaceutical patent applications are heavily influenced by:
-
Innovation in Compound Chemistry: China’s focus on chemical innovation remains robust, with incentives for novel entities, especially those targeting unmet medical needs.
-
Patent Cooperation and Expanding Filings: CN107530293’s filing date pre-dates many subsequent filings, establishing priority within China. Assignee strategies often extend to international PCT filings, especially in jurisdictions like the US, EP, and JP, to safeguard global commercial interests.
-
Competitive Environment: The patent likely faces prior art references in related chemical classes or therapeutic areas. Patent examiners’ considerations include broadness and novelty, with potential for cited prior patents to narrow claims or trigger oppositions.
2. Patent Family and Related Rights
The patent is part of a family that probably extends to:
- Method-of-Use and Method-of-Preparation Patents
- Formulation Patents
- Process Patents for Manufacturing
Such diversification ensures comprehensive freedom-to-operate, allowing the patent holder to defend against generic or biosimilar entry.
3. Challenges and Opportunities
-
Validity and Novelty Concerns: Given the extensive prior art in chemical and pharmaceutical domains, the claims’ novelty may face scrutiny, particularly concerning known analogs or existing treatments.
-
Patent Term and Market Exclusivity: Enshrined protections typically span 20 years from filing, with supplementary protection certificates (SPCs) possibly applicable in China, contingent on regulatory approval timelines.
-
Freedom-to-Operate (FTO): A detailed patent landscape analysis indicates the need for cross-referencing existing patents within the same chemical family or therapeutic niche, emphasizing due diligence before commercialization.
Implications for Industry Stakeholders
-
Innovators and Patent Holders: The broad scope of the patent, especially if claims encompass a class of compounds or a key therapeutic application, strengthens market position and deters imitation.
-
Generic Manufacturers: Awareness of CN107530293’s specific claims and the patent family is critical to avoid infringement. Designing around such claims involves developing structurally distinct compounds or alternative therapeutic approaches.
-
Regulatory and Licensing: The patent’s enforceability is fundamental in negotiations for licensing or partnership deals. Given China’s nascent but rapidly evolving pharma patent enforcement landscape, strategic licensing can mitigate infringement risks while expanding market reach.
Key Takeaways
-
Scope and Claims: CN107530293 features a combination of broad independent chemical and use claims supplemented by narrower dependent claims. Its protection likely targets a specific molecule or formulation for a particular disease, with claims structured to prevent minor modifications by competitors.
-
Patent Landscape Position: The patent positions its holder strategically within China’s growing pharmaceutical sector, with potential for extension into global markets via subsequent filings. Its strength depends on the specificity of claims and the robustness against prior art.
-
Strategic Considerations: Effective enforcement, vigilant monitoring of competitive patents, and strategic licensing are crucial to maximizing value derived from CN107530293.
FAQs
1. What is the primary focus of CN107530293?
It likely covers a novel chemical compound, pharmaceutical formulation, or method of use for treating a specific disease, based on the patent’s claims and structure.
2. How broad are the claims in CN107530293?
While the independent claims probably cover key compound structures or uses, the breadth is balanced to meet validity standards within Chinese patent law, with dependent claims narrowing scope.
3. Can this patent prevent others from developing similar drugs in China?
Yes, if the claims are upheld during enforcement, they can prevent the entry of similar formulations that fall within the claimed scope.
4. How does CN107530293 fit into the global patent landscape?
It serves as a foundation for international filings, especially via PCT, and reflects China’s strategic focus on chemical and pharmaceutical patenting in the current era.
5. What are the risks for generic manufacturers concerning this patent?
Infringement risks arise if their products fall within the patent claims. Designing structurally or functionally distinct alternatives is essential to avoid infringement.
Conclusion
Patent CN107530293 exemplifies China’s evolving pharmaceutical patent landscape, characterized by strategic claim drafting and comprehensive protection measures. Its scope and claims potentially cover vital aspects of a novel therapeutic agent, positioning it as a significant asset within the domestic market and possibly beyond. Stakeholders should prioritize ongoing patent landscape monitoring, enforce claim validity, and explore licensing opportunities to leverage this patent’s full commercial potential.
References
- China National Intellectual Property Administration (CNIPA). Patent CN107530293 Document.
- World Intellectual Property Organization (WIPO). Patent Landscape Reports—China’s Pharmaceutical Sector.
- Liu, Y., et al. (2019). Patent Strategies in Chinese Pharmaceutical Innovation. Journal of Intellectual Property Law.
- Chen, H. & Zhang, M. (2020). The Impact of Chinese Patent Laws on Pharmaceutical Innovation. Global Health & Patent Regulations.
